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Summary The concentrations of glutathione S-transferase (GST) B, and B2 (Alpha), Pi and Mu have been
measured by radioimmunoassay in cytosols from 28 oestrogen receptor (ER) rich and 30 ER-poor breast
tumours. GST B1, B2 and Pi was detected in all 58 breast tumour cytosols whilst GST Mu was found in only
28. Of the GSTs, Pi was expressed most strongly in all cytosols and the concentration was significantly higher
in ER-poor tumour cytosols than in ER-rich tumours (P<0.01). As with GST Pi, the highest levels of GST B,
and GST B2 were found in ER-poor tumour cytosols; the levels of GST B, and GST B2 were positively
correlated (r=0.66, P<0.001). No quantitative or qualitative association was found between ER status and
GST Mu which was expressed in 46% of ER-rich and 50% of ER-poor tumour cytosols. No relationship
could be found between GST expression and age, menopausal status, lymph node involvement or tumour T
stage in the subgroup of patients in whom this information was available. These data suggest that a common
mechanism is responsible for GST induction in ER-poor tumours and that the nulled Mu phenotype has no
increased susceptibility to developing breast cancer.
The glutathione S-transferases (GST) are a family of dimeric
enzymes which are found in the cell cytoplasm. They have
been implicated in the detoxification of a wide range of
xenobiotics and chemotherapeutic agents (Jakoby, 1978;
Mannervik, 1985; Buller et al., 1987). Three immunologically
distinct major classes of GST occur in humans Alpha (that
comprises B, and B2 subunits), Mu and Pi (Mannervik et al.,
1985; Stockman et al., 1985). Although present in most
human cells, the expression of the various GST isoenzymes
may vary between different types of tissue (Strange et al.,
1984). Approximately half the population do not express
GST Mu and appear more susceptible to developing lung
cancer if they smoke heavily (Seidegard et al., 1986). GST Pi
has been associated with pre-neoplastic and neoplastic
change and may be present in many human tumours and cell
lines (Ilio et al., 1986; Kodate et al., 1986; Shiratori et al.,
1987; Shea et al., 1988; Mannervik et al., 1987).
Using a cDNA probe, over-expression of GST Pi RNA
has been found in a multidrug-resistant cell line of breast
cancer and also in a small series of 21 breast cancers (Mos-
cow et al., 1988). In the same study an inverse correlation
was found between expression of GST Pi and the oestrogen
receptor levels in the tumour. The expression of the Alpha
and Mu classes of GST was not measured.
In the present study we have used specific radioimmunoas-
says to measure the expression, at the protein level, of GST
Pi, Mu, B, and B2 in cytosols from a larger group of 58
breast cancers.
Methods
Patients
Fifty-eight women with histologically proven invasive breast
cancer were studied. Apart from four patients (three treated
with tamoxifen and one with chemotherapy), none had
received prior therapy for their malignancy.
Tumour was obtained from the primary cancer in 53 cases
and from an axillary lymph node invaded with cancer in the
remaining five individuals. The tumours were transported on
ice to a cold room and then stored in liquid nitrogen until
assayed.
Cytosolpreparation
All procedures were performed at 0-4°C. Tumour was
dissected from surrounding fat and connective tissue, finely
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cut with scissors and homogenised in 20 mmol 1-' Tris
buffer, pH 7.5 (w/v 1:10), using a Silverson homogeniser at
maximum speed for 20s, then 15 with min interval for
cooling. The homogenate was then centrifuged at 105, 000 g
for 1 h and the resultant supernatant was used as a cytosol.
Oestrogen receptors
Oestrogen receptors were measured in an adjacent portion of
tumour by saturation analysis (Hawkins et al., 1981).
Tumour cytosol was incubated overnight at 4°C with 3H-17
P-oestradiol. Separation of free and bound steroid was by
addition of dextran-coated charcoal; the bound fraction was
measured by liquid scintillation counting. Concentration of
receptors was determined by Scatchard analysis (Scatchard,
1949). Activities below 20 pmol mg-' cytosol protein were
designated oestrogen receptor poor (ER-poor) and those with
activities in excess of 20 pmol mg-' cytosol protein as ER-
rich.
Measurement ofGST concentrations
Specific radioimmunoassays, described in detail previously
(Beckett & Hayes, 1984; Hussey et al., 1987; Howie et al.,
1988), were used to determine the concentration of GST Pi,
GST Mu, GST B1 and GST B2 isoenzymes in the 58 breast
cytosols. The standards used for the B1, B2 and Mu assays
were purified from human liver obtained from transplant
donors and for GST Pi from fresh human placenta.
The cytosol, if required, was diluted in assay diluent con-
sisting of 25 mmol 1' sodium phosphate buffer pH 7.6
bovine serum albumin (1 g 1') and sodium azide (0.2 g 1-l)
before analysis. Within-assay coefficients of variation of less
than 10% was achieved in all assays.
Protein measurement
The dye binding technique described by Bradford (1976),
adapted for use on a Cobas Fara (Roche Diagnostic Ltd,
Welwyn Garden City, UK) centrifugal analyser was used for
total protein estimation.
Results
The median levels of each of the GST isoenzymes in the
breast cytosols are shown in Table I. GST Pi, B, and B2 were
detected in all breast tumour cytosols, whereas GST Mu was
found in only 28 (48%) of the 58 cytosols. GST Pi was
expressed most strongly with concentrations ranging from 30
to 1,110fig.g-' cytosolic protein. For GST B, and B2 the
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Table I Median GST levels
Median GST concentrations (ttg GSTg-' protein)
B, B2 Pi Mu
All tumours 4.5 0.86 222 118
(n = 58)
ER-rich tumours 3.6 0.98 198 183 (n = 28)
ER-poor tumours
(n= 30) 4.7 0.82 306 107
ForGST Mu, dataisgiven foronlythe 28 tumours thatexpressedthe
protein.
concentrations ranged from 0.6 to 48ltg g-' cytosolic protein
and 0.04 to 5.3 fig g-' cytosolic protein, respectively (Figure
1). The levels of B, and B2 were positively correlated
(r = 0.66, P<0.001) but GST Pi did not correlate with the
expression of other GST.
The concentrations of GST in the cytosols subdivided
according to the ER status as shown in Figure 1. Levels of
GST Pi were significantly higher in ER-poor tumours
(P<0.01, Mann-Whitney U test). Indeed, the tumours with
the 11 highest GST Pi values were in the ER-poor tumours.
As with GST Pi, the highest levels of GST B1 and GST B2
were observed in ER-poor tumours with the eight highest
GST B, values being found in the ER-poor tumour group.
However, when compared as groups the differences in GST
B, and GST B2 between ER-rich and ER-poor tumours did
not reach statistical significance. No significant correlation
could be found in the quantitative levels of oestrogen recep-
tors and the expression of any of the GST classes.
No association was found between GST Mu and ER
status. GST Mu was present in 15 of the 30 ER-poor
tumours and 13 of the 28 ER-rich tumours. The same pat-
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tern of GST expression between groups was observed if a
level of <5 pmol mg-' was used to define ER status.
There was no relationship between levels of GSTs and the
age or menopausal status of the patients from whom the
tumour was derived. Furthermore, no obvious association
was apparent between GST and lymph node involvement or
tumour T stage in the subgroup of patients in whom this
information was available. Similarly, there was no indication
that tumour cellularity, central necrosis or a special his-
tological type was associated with increased expression of
GSTs.
The frequency with which GST Mu was expressed in the
breast cancers was not significantly different from the fre-
quency of expression of GST Mu found using lymphocytes
obtained from a group of 42 laboratory volunteers where 23
(55%) volunteers expressed the enzyme (test of confidence
limits for a proportion; Snedecor & Cochran, 1974).
Discussion
Our results concerning the elevated expression of GST Pi in
ER-poor breast cancer are compatible with the data of Mos-
cow et al. (1988), who showed increased mRNA levels for
GST Pi in a similar group of tumours. This suggests that
raised mRNA levels in ER-poor tumours results in an in-
creased production of GST Pi protein. In addition, we have
shown that both B, and B2 GST appear to be over-expressed
in some ER-poor tumours.
Although the role of GST Pi in conferring drug resistance
has been recently questioned (Yusa et al., 1988) an associa-
tion between GST Pi expression and acquisition of drug
resistance has been widely reported (for review see Hayes &
Wolf, 1988). It has been suggested that the increased levels of
GST Pi in ER-poor tumours will confer a poorer prognosis
because such patients will have a lesser chance of responding
to chemotherapeutic agents (Moscow et al., 1988). However,
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Figure 1 Concentrations of GST class Alpha (B1 and B2) and Pi and mu in oestrogen receptor rich (ER + ) and poor (ER-)
breast tumours (0). Tumours in which the concentration of GST Pi exceeded 4001g g-' cytosolic protein are shown by 0.836 A.F. HOWIE et al.
it should be noted that ER-poor tumours often have a high
proliferation rate (Meyer et al., 1977) and this can be
associated with rapid response to chemotherapy (Stoll, 1986).
Additionally, there is no consensus on whether response rates
to chemotherapy differ significantly in ER-rich and ER-poor
tumours (Hawkins et al., 1980; Carle et al., 1984). In rat
mammary tumours increases in the Alpha class GST are also
associated with resistance to chemotherapeutic agents (Buller
et al., 1987). In our study 11 ER-poor tumours over-
expressed GST Pi while six and four ER-poor tumour over-
expressed GST B, and GST B2, respectively. However, we
have no clinical evidence that these increased Alpha class and
Pi class GST levels are associated with chemotherapeutic
insensitivity.
Aquisition ofmulti drug resistance in MCF-7 breast cancer
cells is associated not only with an increase in GST Pi
expression but also with a loss of hormone sensitivity. Our
data show that both GST Pi and Alpha class GST expression
is inversely linked to ER status. These observations are of
interest since ER-poor tumours as a group are associated
with worse prognosis than those which are ER-rich
(McGuire et al., 1975a; Nicolson et al., 1981; Hawkins et al.,
1987; Courdi et al., 1988). Whether this results from ER-rich
cancers being inherently more indolent or more likely to
respond to steroid hormone deprivation therapy is not clear
(Howell et al., 1984; Saez et al., 1983; Adami et al., 1985).
However, it also has to be emphasised that whereas ER-poor
tumours rarely respond to hormone manipulation (McGuire
et al., 1975b; Le Clerq & Heuson, 1977), the present results
showed that only a small proportion of ER-poor tumours
have elevated levels of GST. In this respect the observation
that ER-negative breast cancers can be divided into sub-
groups on the basis of other tumour characteristics such as
epidermal growth factor receptors, vimentin and p53 expres-
sion is relevant (Cattoretti et al., 1988). In the case of EGF
receptors, this may be of prognostic value (Sainsbury et al.,
1987) but it is not known if there is an association between
GST Pi expression and EGF receptor levels. It will be of
interest to know whether patients having tumour with over-
expression of GST will return more quickly with recurrent
disease than those with lower GST, irrespective of ER status.
GST Pi maps to chromosome 11 (Moscow et al., 1988),
which has an increased incidence of deletions in ER-poor
tumour cells when compared to ER-rich tumours (Ali et al.,
1987). These observations have led to the suggestion ofa link
between over-expression of GST Pi and a specific deletion on
chromosome 11. The Alpha class of GST, however, map to
chromosome 6 (Board & Webb, 1987) and we have shown
that both GST B, and GST B2 are also over-expressed in
some ER-poor tumours. These data suggest that there may
be a common mechanism, rather than specific chromosomal
deletions, that leads to over-expression of the GST in certain
breast cancers.
The incidence of GST Mu expression in both the ER-rich
and ER-poor breast tumours was not significantly different
from the incidence of GST Mu expression found in lym-
phocytes from the normal population (Seidegard et al., 1986;
Hussey et al., 1987). This suggests a lack of association
between expression of GST Mu and breast cancer.
In summary, glutathione S-transferases B,, B2 and Pi have
been found in all cytosols of breast cancer whereas Mu was
detected in only about one-half. High levels of GST B,, B2
and Pi were limited to ER-poor tumours, the clinical
significance of which merits further study.
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